Years Change in group size resulting from a general screening program Total diabetes-related costs under actual practice Total diabetes-related costs with a screening program Gross benefit
Group 1 Group 2 Group 3 Group 4
2013 0 0 0 0 18,700,000,000 € 18,700,000,000 € -
2014 2,916 3,188 -3,621 -2,483 19,666,666,667 € 19,611,005,509 € 55,661,157 €
2015 5,535 6,120 -6,587 -5,007 20,633,33,333 € 20,521,702,557 € 111,630,065 €
2016 7,905 8,826 -8,997 -7,552 21,600,000,000 € 21,432,369,935 € 167,630,065 €
2017 10,061 11,330 -10,933 -10,103 22,566,666,667 € 22,343,227,837 € 223,438,830 €
2018 12,035 13,655 -12,466 -12,647 23,544,333,333 € 23,254,448,529 € 278,884,805 €
Cumulated gross benefit 837,245,633 €
Table 2: Effects of a general screening program of small fiber neuropathy on the distribution of patients among severity groups and on the gross benefit.